Clinical trial · Interventional
Anesthesia and Non-small Cell Lung Cancer Recurrence
Recurrence Free Survival After Curative Resection of Non-small Cell Lung Cancer Between Inhalational Gas Anesthesia and Propofol-based Total IntraVenous Anesthesia: a Multicenter, Randomized, Clinical Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
There has been ongoing debate about the relationship between cancer recurrence and anesthetic management. Therefore, the investigators will test the hypothesis that the recurrence free survival (RFS) after curative resection of NSCLC is higher in patient who received total intravenous anesthesia (TIVA) than volatile anesthetics in this multi-center randomized trials.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anesthesia | — | UNRESOLVED | — |
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Surgery | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Inhaled anesthetics | Drug | — | UNRESOLVED |
| Propofol | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- TIVA group
- description
- The TIVA group will receive propofol for both induction and maintenance of general anesthesia.
- interventionNames
- Drug: Propofol
- type
- ACTIVE_COMPARATOR
- label
- GAS group
- description
- The GAS group will receive one or more volatile anesthetics (sevoflurane, desflurane, or isoflurane) for induction and maintenance of anesthesia during the surgery. For GAS group, propofol, midazolam, remimazolam, etomidate, or ketamine can be used with inhalation agents as co-induction agents under the discretion of the attending anesthesiologist.
- interventionNames
- Drug: Inhaled anesthetics
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * American Society of Anesthesiologists physical status (ASA) Ⅰ-Ⅲ * The Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Lung resection surgery (segmentectomy, lobectomy, bilobectomy, pneumonectomy; video-assisted, robot-assisted, or open) with curative intent for NSCLC (clinical Tumor, Node, Metastasis (TNM) stage Ⅰ- ⅢA). Exclusion Criteria: * Distant metastasis or malignant tumor in other organs that according to the attending surgeon is not in long-term remission * Severe neurologic conditions * Severe hepatic disease (Child-Pugh classification C) * Renal failure requiring renal replacement therapy * History of anesthesia and/or surgery within 1 yr * Previous surgery due to lung cancer (except diagnostic biopsies) * Contraindications to any study medication (history of allergy, hypersensitivity reaction, or any other contraindication) * Planned joint extrapulmonary procedure * Surgery under cardiopulmonary bypass or extracorporeal membrane oxygenation * Postoperative sedation * Pregnancy, or lactation * Patient refusal.
References
Publications (1)
- DERIVEDKim J, Yoon S, Song IK, Lee K, Hwang W, Kim H, Lee DK, Lim HK, Kim SH, Lee JW, Hong B, Blank RS, Pedoto A, Popescu W, Theresa G, Martin AK, Patteril M, Pathanasethpong A, Thongsuk Y, Pisitpitayasaree T, Huang A, Yu H, Kapoor PM, Kim K, Chi SA, Ahn HJ. Recurrence-free survival after curative resection of non-small cell lung cancer between inhalational gas anesthesia and propofol-based total intravenous anesthesia: a multicenter, randomized, clinical trial (GAS TIVA trial): protocol description. Perioper Med (Lond). 2024 Jul 23;13(1):79. doi: 10.1186/s13741-024-00436-1. PMID 39039548